MetaCap

Latigo Biotherapeutics (LTGO) vs Mentari Therapeutics (MTRI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Latigo Biotherapeutics is the larger company by market cap ($861.9 million vs $856.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LTGO-32.64%MTRI+0.68%
+40%+1%-38%
Aug 17, 20261 yearNov 20, 2026
LTGO-41.89%MTRI+0.68%
+31%-8%-47%
Aug 17, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LTGO versus MTRI key metrics
MetricLTGOMTRI
Share price$13.00$14.70
Market cap$861.89M$856.94M
1-day change-1.81%-3.57%
EPS (TTM)$-6.07—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$25.93$23.30
52-week low$10.24$5.75
Distance from 52-week high-49.87%-36.91%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+301.92%—
Average volume309.60K19.42K
Shares outstanding66.30M58.30M
Employees66—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Latigo Biotherapeutics

LTGO stock →

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.

Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees

About Mentari Therapeutics

MTRI stock →

Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways.

Health Care · Biotechnology: Pharmaceutical Preparations

LTGO vs MTRI FAQ

Which is bigger, Latigo Biotherapeutics or Mentari Therapeutics?

Latigo Biotherapeutics (LTGO) is larger, with a market capitalization of $861.89M compared with $856.94M for Mentari Therapeutics (MTRI).

Are Latigo Biotherapeutics and Mentari Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons